Immune response to haptenized tumor antigen as possible mechanism of anticancer action of hypoxic bioreductive agents at low doses

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Possible anticancer effect mechanism of hypoxic bioreductive agents (HBA) at low nongenotoxic doses are reviewed. Experimental and clinical investigations show the process which can develop step-by-step when injecting HBA into the tumor-bearing organism resulting in the stimulation of antitumor immunity: HBA activation in hypoxic tumor tissue, conjugation of activated HBA with proteins of tumor cells, antigen processing, presentation of neoantigen epitops in association with major histocompatibility complex-I and cytolysis of these tumor cells by T-killers. The present process can be a variant of the delayed-type hypersensitivity reaction in the tumor region. The direct regulating influence of HBA on immunocompetent and/or tumor cells as a result of interaction of these drugs with superficial or intercellular receptors is supposed to be realized additively with this process. It is concluded that the ability of HBA to selective activation in tumor tissue and formation of immunogenic conjugates with tumor proteins can be a starting- point for developing drugs with immunomodulation anticancer properties.

Original languageEnglish
Pages (from-to)291-296
Number of pages6
JournalCancer Biotherapy and Radiopharmaceuticals
Volume14
Issue number4
Publication statusPublished - 1999
Externally publishedYes

Fingerprint

Neoplasm Antigens
Neoplasms
Antigen Presentation
Immunomodulation
Delayed Hypersensitivity
Major Histocompatibility Complex
Drug Interactions
Immunity
Proteins
Pharmaceutical Preparations

Keywords

  • Bioreductive agent
  • Delayed-type hypersensitivity reaction
  • Hapten-modified tumor antigen
  • Hypoxia
  • Low-dose anticancer chemotherapy
  • Radiosensitizer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

@article{66f54a4503904179a4e78a79143912ff,
title = "Immune response to haptenized tumor antigen as possible mechanism of anticancer action of hypoxic bioreductive agents at low doses",
abstract = "Possible anticancer effect mechanism of hypoxic bioreductive agents (HBA) at low nongenotoxic doses are reviewed. Experimental and clinical investigations show the process which can develop step-by-step when injecting HBA into the tumor-bearing organism resulting in the stimulation of antitumor immunity: HBA activation in hypoxic tumor tissue, conjugation of activated HBA with proteins of tumor cells, antigen processing, presentation of neoantigen epitops in association with major histocompatibility complex-I and cytolysis of these tumor cells by T-killers. The present process can be a variant of the delayed-type hypersensitivity reaction in the tumor region. The direct regulating influence of HBA on immunocompetent and/or tumor cells as a result of interaction of these drugs with superficial or intercellular receptors is supposed to be realized additively with this process. It is concluded that the ability of HBA to selective activation in tumor tissue and formation of immunogenic conjugates with tumor proteins can be a starting- point for developing drugs with immunomodulation anticancer properties.",
keywords = "Bioreductive agent, Delayed-type hypersensitivity reaction, Hapten-modified tumor antigen, Hypoxia, Low-dose anticancer chemotherapy, Radiosensitizer",
author = "Igor Schepetkin",
year = "1999",
language = "English",
volume = "14",
pages = "291--296",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Immune response to haptenized tumor antigen as possible mechanism of anticancer action of hypoxic bioreductive agents at low doses

AU - Schepetkin, Igor

PY - 1999

Y1 - 1999

N2 - Possible anticancer effect mechanism of hypoxic bioreductive agents (HBA) at low nongenotoxic doses are reviewed. Experimental and clinical investigations show the process which can develop step-by-step when injecting HBA into the tumor-bearing organism resulting in the stimulation of antitumor immunity: HBA activation in hypoxic tumor tissue, conjugation of activated HBA with proteins of tumor cells, antigen processing, presentation of neoantigen epitops in association with major histocompatibility complex-I and cytolysis of these tumor cells by T-killers. The present process can be a variant of the delayed-type hypersensitivity reaction in the tumor region. The direct regulating influence of HBA on immunocompetent and/or tumor cells as a result of interaction of these drugs with superficial or intercellular receptors is supposed to be realized additively with this process. It is concluded that the ability of HBA to selective activation in tumor tissue and formation of immunogenic conjugates with tumor proteins can be a starting- point for developing drugs with immunomodulation anticancer properties.

AB - Possible anticancer effect mechanism of hypoxic bioreductive agents (HBA) at low nongenotoxic doses are reviewed. Experimental and clinical investigations show the process which can develop step-by-step when injecting HBA into the tumor-bearing organism resulting in the stimulation of antitumor immunity: HBA activation in hypoxic tumor tissue, conjugation of activated HBA with proteins of tumor cells, antigen processing, presentation of neoantigen epitops in association with major histocompatibility complex-I and cytolysis of these tumor cells by T-killers. The present process can be a variant of the delayed-type hypersensitivity reaction in the tumor region. The direct regulating influence of HBA on immunocompetent and/or tumor cells as a result of interaction of these drugs with superficial or intercellular receptors is supposed to be realized additively with this process. It is concluded that the ability of HBA to selective activation in tumor tissue and formation of immunogenic conjugates with tumor proteins can be a starting- point for developing drugs with immunomodulation anticancer properties.

KW - Bioreductive agent

KW - Delayed-type hypersensitivity reaction

KW - Hapten-modified tumor antigen

KW - Hypoxia

KW - Low-dose anticancer chemotherapy

KW - Radiosensitizer

UR - http://www.scopus.com/inward/record.url?scp=0032766009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032766009&partnerID=8YFLogxK

M3 - Review article

VL - 14

SP - 291

EP - 296

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 4

ER -